Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia

Raja Padidela, Michael P. Whyte, Francis H. Glorieux, Craig F. Munns, Leanne M. Ward, Ola Nilsson, Anthony A. Portale, Jill H. Simmons, Noriyuki Namba, Hae Il Cheong, Pisit Pitukcheewanont, Etienne Sochett, Wolfgang Högler, Koji Muroya, Hiroyuki Tanaka, Gary S. Gottesman, Andrew Biggin, Farzana Perwad, Angela Williams, Annabel NixonWei Sun, Angel Chen, Alison Skrinar, Erik A. Imel

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia'. Together they form a unique fingerprint.

Medicine & Life Sciences